OSK1 (α-KTx3.7) is a 38-residue toxin cross-linked by three disulphide bridges that was initially isolated from the venom of the Asian scorpion Orthochirus scrobiculosus. OSK1 and several structural analogues were produced by solid-phase chemical synthesis, and were tested for lethality in mice and for their efficacy in blocking a series of 14 voltage-gated and Ca 2+ -activated K + channels in vitro. In the present paper, we report that OSK1 is lethal in mice by intracerebroventricular injection, with a LD 50 (50 % lethal dose) value of 2 µg/kg. OSK1 blocks K v 1. 
INTRODUCTION
OSK1 is a toxin initially purified from the venom of the central Asian scorpion Orthochirus scrobiculosus [1] . It is a 38-residue peptide cross-linked by three disulphide bridges that are organized according to the conventional pattern of the threedisulphide-bridged scorpion toxins (i.e. C1-C4, C2-C5 and C3-C6) [1, 2] . The 3D (three-dimensional) structure of natural OSK1 in solution, determined by 1 H-NMR [1] , shows that the toxin adopts the α/β scaffold (i.e. an α-helix connected to an antiparallel β-sheet by two disulphide bridges) common to most characterized scorpion toxins, independent of their size and selectivity towards the various ion channels [3] . Together with KTx1 (kaliotoxin 1) [4] , AgTx1-3 (agitoxin 1-3) [5] and BmKTx (Buthus martensi kaliotoxin) [6] , OSK1 belongs to a structural class referred to as α-KTx3 toxins that share between 68 and 90 % sequence identity with each other [7] . According to this nomenclature, OSK1 has been termed α-KTx3.7 [8] . OSK1 has been described previously to block apamin-insensitive smallconductance Ca 2+ -activated channels in neuroblastoma-glioma NG108-15 hybrid cells [9] , which are most likely to be identical with K Ca 3.1 channel. Although the solution structure of OSK1 has been solved [1] (Protein Data Bank code 1SCO), characterization of its pharmacological properties still remained poor. In the present paper, we describe the chemical production and characterization of OSK1. The synthetic product was verified to be indistinguishable from natural OSK1 using two-dimensional 1 H-NMR, and an extensive analysis of its pharmacological profile was achieved, demonstrating that it behaves in vitro as a potent inhibitor of a large array of K + channel subtypes. Structural analogues of OSK1, in which we introduced selective mutations of amino acid residues that are conserved in all members of the α-KTx3 toxin family, except OSK1, were also produced and tested for their pharmacology on various K + channel types.
EXPERIMENTAL Materials
Fmoc (N α -fluoren-9-ylmethyloxycarbonyl)-L-amino acids and reagents used for peptide synthesis were obtained from PerkinElmer (Shelton, CT, U.S.A.). Fmoc-Lys(t-butyloxycarbonyl)-2-chlorotrityl resin was purchased from Advanced ChemTech (Cambridge, U.K.). Solvents were analytical grade products from SDS (Peypin, France). 50 , 50 % lethal dose; MALDI-TOF, matrix-assisted laser-desorption ionization-time-of-flight; NOE, nuclear Overhauser effect; OSK1, toxin 1 from the scorpion Orthochirus scrobiculosus (α-KTx3.7); t-Bu, t-butyl; TFA, trifluoroacetic acid; 3D, three-dimensional. 1 To whom correspondence should be addressed (email sabatier.jm@jean-roche.univ-mrs.fr).
Fmoc-Lys(t-butyloxycarbonyl)-2-chlorotrityl resin (1 % crosslinked; 0.69 mmol of amino group/g) using 1 mmol of Fmoc-L-amino acid derivatives [10] . The side-chain-protecting groups used for trifunctional residues were: Trt (trityl) for cysteine, asparagine, histidine and glutamine; t-Bu (t-butyl) for serine, threonine, tyrosine, aspartate and glutamate; Pmc (pentamethylchroman) for arginine; and Boc (t-butyloxycarbonyl) for lysine. N α -amino groups were deprotected by successively treating with 18 and 20 % (v/v) piperidine/N-methylpyrrolidone for 3 and 8 min respectively. After three washes with N-methylpyrrolidone, the Fmoc-amino acid derivatives were coupled (20 min) as their hydroxybenzotriazole-active esters in N-methylpyrrolidone (2.5-fold excess). After complete assembly of the peptides, and removal of their N-terminal Fmoc groups, the peptide resins (approx. 2.4 g) were treated under stirring for 2.5 h at 25
• C with mixtures of TFA (trifluoroacetic acid)/water/thioanisole/ethanedithiol (88:5:5:2, by vol.) in the presence of crystalline phenol (2.25 g) in final volumes of 30 ml/g of peptide resins. The peptide mixtures were filtered, precipitated and washed twice with cold diethyl oxide. The crude peptides were pelleted by centrifugation (3000 g for 10 min). The crude peptides were then dissolved in water and freeze-dried. Reduced peptides were solubilized (approx. 0.8 mM) in 0.2 M Tris/HCl buffer, pH 8.3, for oxidative folding (40-140 h, depending on the analogue, 22
• C). All peptides were purified to homogeneity by reversed-phase HPLC (PerkinElmer; C 18 Aquapore ODS 20 µm, 250 mm × 10 mm) by means of a 60-min linear gradient of 0.08 % (v/v) TFA/0-35 % acetonitrile in 0.1 % (v/v) TFA/water at a flow rate of 6 ml/min (λ = 230 nm). The purity and identity of the peptides were assessed by: (i) analytical C 18 reversed-phase HPLC (Merck; C 18 Lichrospher 5 µm, 4 mm × 200 mm) using a 60-min linear gradient of 0.08 % (v/v) TFA/0-60 % acetonitrile in 0.1 % (v/v) TFA/water at a flow rate of 1 ml/min; (ii) Edman sequencing; and (iii) molecular mass determination by MALDI-TOF (matrixassisted laser-desorption ionization-time-of-flight) MS.
Conformational analyses of OSK1 by two-dimensional 1 H-NMR and of its analogues by one-dimensional 1 H-NMR
Peptides were dissolved in a mixture of H 2 O/ 2 H 2 O (9:1, v/v) at final concentrations of 10 −3 M (OSK1) or 50 µM (OSK1 analogues). All 1 H-NMR measurements were obtained on a Bruker DRX 500 spectrometer equipped with an HCN probe, and selfshielded triple-axis gradients were used. The experiments were performed at 300 K.
Neurotoxicity of the peptides in mice
OSK1 and its analogues were tested in vivo for toxicity by determining the LD 50 (50 % lethal dose) after intracerebroventricular injection into 20 g C57/BL6 mice (approved by the French ethics committee; animal testing agreement number 006573 delivered by the National Department 'Santé et Protection Animales, Ministère de l'Agriculture et de la Pêche'). Groups of four to six mice per dose were injected with 5 µl of peptide solution containing 0.1 % (w/v) BSA and 0.9 % (w/v) NaCl.
Cells
L929 and MEL (murine erythroleukaemia) cells stably expressing mouse K v 1.3 (mK v 1.3), human K v 1.5 (hK v 1.5) and mouse K v 3.1 (mK v 3.1) channels, and COS-7 cells were maintained in DMEM (Dulbecco's modified Eagle's medium) with Earle's salts (Gibco, Paisley, U.K.) and 10 % (v/v) heat-inactivated FCS (foetal calf serum) (PAA Laboratories, Pasching, Austria) as described previously [11] . The tsA cell line expressing human K Ca 3.1 (hK Ca 3.1) channels was a gift from Dr Daniel Devor (University of Pittsburgh, Pittsburgh, PA, U.S.A.) and was maintained in MEM (minimal essential medium) with Earle's salts supplemented with Glutamax-I (Gibco), 10 % heat-inactivated FCS and 200 µg/ml geneticin (G418). Cells were kept at 37
• C in a humidified incubator containing 5 % (for the L929 cell line expressing mK v 3.1 channel) or 10 % CO 2 3) channel, were co-transfected together with a GFP construct. Currents were measured 1-3 days after transfection. In all cases, FuGene6 Transfection Reagent (Roche, Mannheim, Germany) was used for transfection, according to the recommended protocol.
Electrophysiological recordings
All experiments were carried out at room temperature (22) (23) (24) (25) • C) using the whole-cell recording mode of the patch-clamp technique [12, 13] . Cells were bathed with mammalian Ringer's solution containing 160 mM NaCl, 4.5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 and 10 mM Hepes, pH 7.4 (with NaOH), with an osmolarity of 290-320 mOsm. When OSK1 peptides were applied, 0.1 % (w/v) BSA was added to the Ringer's solution. A simple syringe-driven perfusion system was used to exchange the bath solution in the recording chamber. The internal pipette solution used for measuring voltage-gated K + currents contained 155 mM KF, 2 mM MgCl 2 , 10 mM EGTA and 10 mM Hepes, every 10 s. Electrodes were pulled from glass capillaries (Science Products, Hofheim, Germany) in three stages, and fire-polished to resistances measured in the bath of 2.5-5 M . Membrane currents were measured with an EPC-9 or EPC-10 patch-clamp amplifier (HEKA Elektronik, Lambrecht, Germany) interfaced to a Macintosh or PC running acquisition and analysis software (Pulse and PulseFit). When voltage-dependent K + currents were measured, the capacitive and leak currents were subtracted using the P/10 procedure. Series resistance compensation (> 80 %) was employed if the current exceeded 2 nA. The holding potential in all experiments was − 80 mV. Data analyses were performed with IgorPro (WaveMetrics, Lake Oswego, OR, U.S.A.), and K d values were deduced by fitting a modified Hill equation to the data
, where X is the peak current (for K v channels), or the slope of the ramp current, i.e. the conductance, measured between − 100 and − 60 mV (for hK Ca 3.1 and hK Ca 2.3 channels) to the normalized data points obtained at more than four different peptide concentrations. This fit indicates that one peptide molecule is sufficient to block the current through the channel. The S.D.s obtained by this fitting routine reflect the uncertainty of the fit.
RESULTS

Synthesis of OSK1 and its analogues
An alignment of OSK1 and other members of the α-KTx3 family based on the relative positioning of the half-cystine residues is shown in Figure 1(a) . OSK1 displays some interesting structural differences among α-KTx3 toxins. Instead of the basic lysine residue present in all other members of this family, except Bs6, OSK1 possesses an acidic glutamate residue in position 16 . In position 20, where all other toxins contain an acidic aspartate residue, OSK1 has a basic lysine residue. Another distinguishing feature of OSK1 is the presence of a basic arginine residue at position 12 instead of an uncharged proline or glycine residue in all other α-KTx3 toxins. Also, similar to all other α-KTx3 toxins, OSK1 exhibits a threonine residue at position 36, where most other several toxin families (α-KTx1, α-KTx2, α-KTx4, α-KTx6 and α-KTx12) display a tyrosine residue. Since the latter residue has often been involved in K + channel interaction as part of toxin 'functional' dyads [2] , we therefore expected that Thr 36 would influence the pharmacology of OSK1 towards K + channels. Accordingly, we produced OSK1 chemically and a series of OSK1 analogues to assess the importance of the specific OSK1 residues Arg 12 , Glu 16 , Lys 20 and Thr 36 ( Figure 1b ). All peptides were prepared by solid-phase synthesis using the stepwise Fmoc/t-Bu chemistry as described in [14] . In all cases, the amounts of target peptides linked to their resins illustrate yields of peptide assemblies ranging from 70 % to 80 %. Accordingly, crude reduced peptides, obtained after TFA treatment, were found to be relatively homogeneous, as shown for OSK1 synthesis (Figure 2a) . The peptides were folded/oxidized under alkaline conditions for 40-120 h (depending on the nature of the molecule), yielding the crude oxidized peptides (see Figure 2b for OSK1). The main oxidized species were purified to > 99 % homogeneity by preparative C 18 reversed-phase HPLC (Figure 2c for OSK1 is shown as an example). The mass spectrometric analyses of the peptides using the MALDI-TOF technique gave experimental molecular masses that are similar to or identical with the deduced molecular masses (Figure 2d) . The yield of each peptide synthesis was approx. 1-3 %. In the case of OSK1, a complete Edman sequencing was also performed to validate its primary structure (results not shown) and check for the presence of standard half-cystine pairings of the type C1-C4, C2-C5 and C3-C6, common to three-disulphide-bridged toxins structured according to an α/β scaffold [1, 15] .
Structural analysis of OSK1 and its analogues by 1 H-NMR
The two-dimensional 1 H-NMR spectrum of synthetic OSK1 is consistent with a peptide folding according to an α/β scaffold, with evidence for α-helical and β-sheet structures (Figure 3a) . These experimental data are consistent with the 3D solution structure of the natural OSK1 solved by 1 H-NMR [1] . We also used one-dimensional 1 H-NMR to verify that the mutations introduced in the OSK1 analogues did not alter folding according to the α/β scaffold (Figure 3b) . Indeed, similar overall distributions of the resonance frequencies of the different peptides indicate that they adopt closely related conformations.
Lethal activity of OSK1 and its analogues in mice
We determined LD 50 values for the synthetic peptides by injecting them intracerebroventricular into mice ( [15] [16] [17] . Assuming that OSK1 would diffuse immediately throughout the entire mouse brain (40 ng of toxin in 400 µl of brain volume) following the injection, the toxin concentration in the brain would be approx. 20 nM. Right at the injection site, the toxin might even briefly reach micromolar concentrations. We therefore believe that the convulsions and the lethality of the OSK1 peptides are caused by inhibition of brain K v 1.1 and K v 1.2 channels (see IC 50 values for these channels in Table 1 and the following section).
Pharmacological activity of OSK1 and its analogues on various K
+ channels
Effects of OSK1
We studied the pharmacological profile of OSK1 on a panel of 14 K + channels (nine voltage-gated and five Ca 2+ -activated K + channels). (Table 1) . Also, OSK1 has no effect on K Ca 2.1, K Ca 2.2, K Ca 2.3 and K Ca 1.1 channels when in the micromolar concentration range, whereas it shows a moderate activity on K Ca 3.1 channel (also referred to as IK1 or SK4) with an IC 50 value of 225 nM. Figure 4 summarizes the effects of OSK1 on the channels that are sensitive to this toxin. It illustrates that saturating concentrations of OSK1 induce a complete block of the outward K + current for each channel type. A comparison of the pharmacological properties of synthetic OSK1 with its natural counterpart was not possible since the latter was not available.
Effects of OSK1 analogues
We have noticed that OSK1 displays two unusual properties for a member of the α-KTx3 family: one structural and one functional. First, some charged amino acid residues differ between OSK1 and other α-KTx3 toxins, such as the acidic Glu 16 and the basic Lys 20 , which are only present in OSK1. At equivalent positions, other toxins have a basic lysine residue and an acidic aspartate residue. One exception to this rule is Bs6 (α-KTx3.8; Figure 1 ) that possesses an uncharged glutamine residue at position 16. Overall, this corresponds to an inversion of charged residues within the OSK1 primary structure. Secondly, OSK1 has an unexpected wide range of activity, i.e. on K v 1.1, K v 1.2 and K v 1.3 channels, a property usually not shared by other toxins from this structural family. We therefore speculated that these two properties might be connected and decided to evaluate the pharmacological impact of restoring the more conventional amino acid residues at relevant positions within the OSK1 sequence (Lys 16 16 ]-OSK1, only slight differences in the pharmacological profile were observed, except the K v 1.3 channel, for which a 4.8-fold decrease in blocking efficacy was found (IC 50 value of 67 pM instead of 14 pM). For [D 20 ]-OSK1, more pronounced effects were observed, with decreased blocking efficacy ranging from 2.5-to 14-fold depending on the ion channel type under consideration (Table 1) . Thus both amino acid residues of OSK1 appear to contribute to differences in toxin selectivity for K v channels. In the case of OSK1, there is a 385-fold difference in blocking efficacy between K v 1.2 and K v 1.3 channels, which is decreased to 78-fold for [K 16 ]-OSK1, and increased to 2102-fold for [D 20 ]-OSK1. The two substitutions therefore generated somehow opposite effects in altering toxin selectivity towards K v channels. We investigated further the potential effects of the double substitution on OSK1 pharmacology. We observed that [K 16 ( Figure 5a ). This value is similar [5] or even better [19, 20] than those reported for the best K v 1.3 channel blockers described hitherto.
Into this most active analogue, we introduced additional substitutions with the aim of determining their impact on OSK1 pharmacology (Figure 1b) 20 ]-OSK1, and from 4-to 36-fold as compared with OSK1 (Figures 5b-5d) . Although decreased blocking efficacy is generally not a sought-after property for analogues, it should be noticed that [P 12 ,K 16 ,D 20 ]-OSK1's potency towards K v 1.3 channel remains high (IC 50 value of 59 pM), and that the difference in blocking efficacy between K v 1.2 and K v 1.3 channels is increased to 3322-fold. Altogether, these results suggest the importance of Arg 12 for OSK1 pharmacology. However, the pharmacological impact of the substitution may be due to either the lack of Arg 12 in toxin sequence or a change of peptide conformation induced by Pro 12 . Next, we investigated the effect of replacing Thr 36 by a tyrosine residue that is found in a homologous position in a number of K v -channel-acting scorpion toxins from other α-KTx families (Figure 1 ). This supplemental mutation in [K 16 ,D 20 ]-OSK1 results in a marked decrease of peptide blocking efficacy towards K v 1.1, K v 1.2 and K v 1.3 channels (from 3.9-to 86-fold, and from 8.7-to 57-fold, as compared with OSK1). Interestingly, we found that [K 16 ,D 20 ,Y 36 ]-OSK1 is significantly active towards K v 1.7 channel [25] (Figure 5e ), albeit with low potency (IC 50 value of 1.5 µM). It is worth noting that none of the other analogues had gained a novel activity so far towards a previously unblocked channel type. Such a channel blockage is of interest, since there is no known inhibitor of this channel type. Future experiments will aim at improving peptide affinity for K v 1.7 channel. 
Each K
+ channel amino acid sequence is numbered and subdivided into structural and/or functional regions (transmembrane segments S5 and S6, turret region, pore helix and selectivity filter). Amino acid sequence identity with K v 1.3 channel is shaded grey. Amino acid residues predicted to interact with OSK1 are denoted by asterisks.
DISCUSSION
Although the 3D structure of OSK1 in solution was solved a few years ago [1] , its pharmacological properties remained to be established. In the present study, for the first time, we have produced synthetic OSK1, along with several structural analogues, and have investigated their biological activities extensively on a wide range of potential K + channel targets. OSK1 is a potent blocker of three different K v channel types (K v 1.1, K v 1.2 and K v 1.3) and a moderate blocker of Ca 2+ -activated K Ca 3.1 channel. Of interest, OSK1 is one of the most powerful K v 1.3 channel blockers so far described, making it an interesting lead compound for the development of new drugs for the therapy of autoimmune disorders [18, [26] [27] [28] [29] . A first step in this direction was taken with the production of [P 12 ,K 16 ,D 20 ]-OSK1, which still shows a high affinity, but an improved selectivity for K v 1.3 channel. Also, [K 16 ,D 20 ]-OSK1 exhibits an increased activity towards K v 1.3 channel (IC 50 value of 3 pM with approx. 100 % of current block) compared with OSK1, which places it among the most potent K v 1.3 channel blockers reported so far [18] . Therefore [K 16 ,D 20 ]-OSK1 (or its derivatives) might be of particular value for the management of memory-T-cell-mediated immune responses, such as multiple sclerosis [18, 29] .
In addition, K v 1.3 and K Ca 3.1 channels have been shown to critically contribute to lymphocyte activation [18, 30] . However, the contribution level of each channel type to lymphocyte K + current is different, depending on the type of activated lymphocytes. K v 1.3 current is predominant in effector memory lymphocytes, whereas K Ca 3.1 current predominates in central memory lymphocytes. An ideal immunomodulatory compound is expected to possess two main properties. First, it should preferentially block either K v 1.3 or K Ca 3.1 channel in order to target one specific subset of T-cells [18] . Secondly, it should be selective for one of these channel types, thus without affecting other K v -variants, in order to avoid unwanted secondary effects. OSK1 presents the first desired property, since it targets K v 1.3 channel with a greater potency than K Ca 3.1 channel. Also, its lower efficacy on other K v -type channels, namely the neuronal variants K v 1.1 and K v 1.2 channels, is a first asset towards the design of an adequate immunosuppressive drug. Designing of improved compounds is possible since several OSK1 analogues already display increased selectivity for K v 1.3 channel. It is worth mentioning that OSK1 thus now belongs to an enlarged family of potent K v 1.3 (α-KTx 1.1, 2.2, 3.2 and 7.1) and/or K Ca 3.1 (α-KTx 1.1 and 6.2) channel immunosuppressive drugs [31, 32] . Forthcoming OSK1-derived analogues will be designed to maintain a high potency on K v 1.3 channel and a diminished activity towards other K v -channels.
To gain insight in the differences of OSK1 affinity for the various K + channels on which this toxin is active, we first compared the amino acid sequences of the pore regions of K Ca 3.1, K v 1.1, K v 1.2 and K v 1.3 channels with a particular emphasis on the last channel type ( Figure 6 ). Noteworthily, K v -type channels mainly differ in the turret region, whereas amino acid sequence differences with K Ca 3.1 channel relies further on the pore helix region. Therefore differences in selectivity may preferentially be attributed to specific interactions of toxin residues with these two regions. In particular, a cluster of acidic residues can be observed in the turret region of K v -type channels, which is not the case in K Ca 3.1 channel. We set out to determine the functional maps of OSK1 on K v 1.1, K v 1.2 and K v 1.3 channels using docking simulations ( Figure 7 ). Of note, the functional map of OSK1 for K Ca 3.1 channel could not be formally determined owing to its weak docking energy. According to these functional maps, the channel residues involved in an interaction with OSK1 are highlighted by asterisks ( Figure 6 ). Amino acid residues of the various K v channels that interact with OSK1 appear to be mainly located in the turret region and in or nearby the selectivity filter. [33] .
Computational simulations (based on Brownian dynamics) with six other toxins, also highly potent on K v 1.3 channel, reveal a slightly distinct pattern of molecular interactions [34] . In particular, two channel residues (Gly 380 and Asp 386 ) were predicted to participate in the interaction with these toxins unlike with OSK1. This suggests that OSK1 has a different docking position over K v 1.3 channel from those of other K v 1.3-channel-acting toxins. Importantly, none of the amino acid residues (Arg 12 , Glu 16 , Lys 20 and Thr 36 ) that were mutated to produce the OSK1 analogues are directly implicated in binding to K v -type channels. For most of these residues (Arg 12 , Glu 16 and Lys 20 ), this was expected, since they belong to the toxin helical structure. Nevertheless, mutating these amino acid residues presumably alters the structure of OSK1, since the docking of [K 16 ,D 20 ]-OSK1 presents a slightly different pattern of molecular contacts, although the same toxin residues are concerned. In particular, [K 16 ,D 20 ]-OSK1 now also interacts with Gly 380 , similar to other K v 1.3-channel-blocking toxins, but different from OSK1 [34] . Globally, these changes in receptor-ligand contacts may be responsible for the increased affinity of [K 16 ,D 20 ]-OSK1 for K v -type channels (especially K v 1.3) over OSK1. In that respect, Gly 380 may be one of the contributors of this increased affinity, since it is present in K v 1.3, but not in K v 1.1 or K v 1.2, channel. Interacting residues from the K v channel are highlighted in red. I to IV before channel residue numbering specifies one of the four α-subunits forming a functional K v channel. Colour codes: yellow (hydrophobic residues), light green (polar residues) and blue (basic residues). These maps were generated by docking simulations [37] . Swiss-Prot accession codes used are P16388 (mouse K v 1.1 channel), P16389 (human K v 1.2 channel) and P16390 (mouse K v 1.3 channel).
Although the docking simulation of OSK1 on the K Ca 3.1 channel was not reliable, there are interesting parallels to draw from the comparative effects of other toxins on both K v 1.3 and K Ca 3.1 channel. Maurotoxin is highly active on K Ca 3.1 channel, but is weakly active on K v 1.3 channel [35] . Conversely, OSK1 is weakly active on K Ca 3.1 channel, but is highly potent on K v 1.3 channel. Thus a comparison of the functional maps of both toxins should provide some insights into the key molecular determinants that drive these differences in channel selectivity. All functional maps are not available, but a few elements help to identify these molecular determinants. We have noticed that Kv1.3 and K Ca 3.1 channels differ mainly in the turret and pore helix regions. However, since docking simulation of OSK1 on to K v 1.3 channel highlights a number of close contacts only in the turret region, this suggests that the latter region may underlie the difference in OSK1 affinity for K v 1.3 and K Ca 3.1 channels. In agreement with this hypothesis was the finding that mutating Lys 32 of α-KTx1.1 (charybdotoxin), a residue which interacts with Asp 376 of the K v 1.3 channel turret region, strongly decreased toxin affinity for K v 1.3 channel without altering affinity for K Ca 3.1 channel [36] . An equivalent lysine residue is present in OSK1 (Lys 32 ), which interacts with Asp 376 from K v 1.3 channel. We thus expect that the higher affinity of OSK1 for K v 1.3 over K Ca 3.1 channel is also partly due to this interaction in the turret region. Although helpful, structural considerations from docking simulations are theoretical, and further experimental validation through targeted point mutations will be needed to confirm the functional importance of the turret region in underlying differences in toxin selectivity.
